Johnson & Johnson agreed November 16 to buy eye-drug developer Ollin Biosciences for $2.2 billion upfront, with Blackstone Life Sciences set to provide $750 million for Phase 3 trials after the acquisition closes, according to the companies’ announcements.
Ollin’s lead experimental antibody, OLN324, is designed to act on VEGF and Ang2, two proteins involved in retinal blood-vessel disease. Ollin is developing it with Innovent Biologics for diabetic macular edema and wet age-related macular degeneration, conditions that can cause vision loss.
J&J could pay up to approximately $1.125 billion more if regulatory and commercial milestones are met. It expects the acquisition to close before the end of 2026, subject to regulatory approvals and customary closing conditions.
Blackstone would pay its development funding to J&J over several years to cover the full Phase 3 program. In exchange, it would be eligible for regulatory and sales milestone payments and single-digit royalties.
Ollin raised $330 million in a June 24 Series B co-led by TCGX and ARCH Venture Partners. That round was intended to fund global Phase 3 development and a second eye-disease program; Blackstone Multi-Asset Investing was among the participants.
In March, Ollin reported 20-week results from its 164-patient Phase 1b JADE trial against faricimab, sold as Vabysmo. Retinal drying was greater with OLN324 in diabetic macular edema but comparable in wet age-related macular degeneration. Vision and retinal-anatomy measures were exploratory; the study’s primary objective was safety and tolerability.